Januvia 25mg Tablet contains Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Sitagliptin enhances the body's ability to regulate blood glucose levels by increasing the levels of incretin hormones, which stimulate insulin release from pancreatic beta cells and decrease glucagon secretion from alpha cells in a glucose-dependent manner. This dual action results in improved glycemic control without causing significant hypoglycemia. Januvia 25mg is typically prescribed as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin or sulfonylureas. The tablet is administered orally once daily, with or without food. Sitagliptin is generally well tolerated; common adverse effects may include nasopharyngitis, headache, and upper respiratory tract infections. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Januvia does not replace insulin and is not indicated for type 1 diabetes or diabetic ketoacidosis. Regular monitoring of blood glucose and renal function is recommended during therapy to optimize treatment outcomes and ensure patient safety.